Hunter Syndrome Treatment Market Size to reach USD 1118.4 Million | Rising in United States and United Kingdom | Fortune Business Insights
The global “Hunter Syndrome Treatment Market” is predicted to reach USD 1,118.4 million by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing R&D investments by key players for the development of novel therapies to treat rare diseases in patients will be critical factor in boosting the Hunter syndrome treatment market growth during the forecast period. Moreover, the rising clinical studies for diabetes and coronary artery disease (CAD) will have a positive impact on market during the forecast period.
In addition, the surge in rare and genetic diseases will uplift
the Hunter syndrome treatment market share. According to the Genetic and Rare
Diseases Information Center (GARD), there can be an estimated 7,000 rare
diseases and the total number of individuals in the U.S. from these rare
diseases can be 25-30 million.
According to the report, published by Fortune Business Insights,
tiled “Hunter Syndrome Treatment Market Size, Share & Industry Analysis, By
Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration
(Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User
(Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026” the market size stood at USD 702.4 million in
2018. The Hunter syndrome treatment market report focuses on demonstrating a complete assessment of the
market. It contains facts, thoughtful insights, historical information,
industry-validated market information, and projections with a suitable set of
assumptions and methodology. It offers valuable insights into all the notable
developments of the market. It is created after extensive research followed by
an all-encompassing analysis to benefit companies, stakeholders, financers, and
potential investors. Moreover, it also includes product launches, acquisitions,
collaborations and partnerships, and industry developments.
Get Request a Sample Copy of the Hunter Syndrome Treatment
Report:
|
North America |
United States, Canada and Mexico |
|
Europe |
Germany, UK, France, Italy, Russia and Turkey
etc. |
|
Asia-Pacific |
China, Japan, Korea, India, Australia, Indonesia,
Thailand, Philippines, Malaysia and Vietnam etc. |
|
South America |
Brazil, Argentina, Columbia etc. |
|
Middle East & Africa |
Saudi Arabia, UAE, Egypt, Nigeria and South
Africa |
Phase II/III Clinical Trials by Shire to
Accelerate Market Prospects
The surge in
clinics trail by prominent companies can spur demand for rare disease
therapeutics, which in turn, will boost the Hunter syndrome treatment market
revenue. For instance, Shire plc, Jersey-registered specialty biopharmaceutical
company announced the results from its Phase II/III clinical trial evaluating
SHP609, previously known as HGT-2310. SHP609 is an investigational formulation
of idursulfase administered intrathecally for a new potential indication for
the treatment of pediatric patients with Hunter syndrome (mucopolysaccharidosis
II or MPS II) and cognitive impairment. Moreover, the growing cases of rare
genetic disorder will impel biopharmaceutical companies to initiate clinical
trials and launch novel drugs, which in turn will create business opportunities
for the market in the forthcoming years. Moreover, the surge in unmet needs of
patients will encourage healthy growth of the Hunter syndrome treatment market
size.
Surge in Orphan Disease to Augment
Growth
The increasing
R&D investments for the development of effective therapies to treat orphan
diseases and Hunter syndrome will have a positive impact on the Hunter syndrome
treatment market during the forecast period. Moreover, the growing number of
orphan disease and rare genetic disease patients will spur demand for Hunter
syndrome treatment, thus boosting the market growth. According to the Genetic
and Rare Diseases Information Center (GARD), there can be an estimated 7,000
rare diseases and the total number of individuals in the U.S. from these rare
diseases can be 25-30 million. As per the U.S. Nation Library of Medicine,
Hunter Syndrome also known as MPS II occurs in approximately 1 in 100,000 to 1
in 170,000 males. Moreover, the ongoing pipeline candidates in Phase 1 and 2 by
biopharmaceutical companies such as ArmaGen, Denali Therapeutics, and REGENXBIO
Inc will propel healthy growth of the market in the forthcoming years. However
high cost associated with therapeutics and lower treatment rates will
subsequently dampen the growth of the market during the forecast period.
Major Hunter Syndrome Treatment Market Key players covered in the
report include:
- Shire
(Takeda Pharmaceutical Company Limited)
- Denali
Therapeutics
- ArmaGen
- Inventiva
- Green
Cross Corp. (GC Pharma)
- CANbridge Life Sciences Ltd.
About Us:
Fortune Business Insights™ delivers accurate data and
innovative corporate analysis, helping organizations of all sizes make
appropriate decisions. We tailor novel solutions for our clients, assisting
them to address various challenges distinct to their businesses. Our aim is to
empower them with holistic market intelligence, providing a granular overview
of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Comments
Post a Comment